Cognitive Protection - Dexmedetomidine and Cognitive Reserve

• Status: Terminated
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• age 65 years and older

• elective major hip replacement or peripheral vascular (major surgery is defined by a planned 2 day hospitalization)

• ASA physical status I-III

• capable and willing to consent

Exclusion Criteria:

• Cardiac surgery

• Intracranial Surgery

• Emergency Surgery

• Patients with severe visual or auditory disorder/handicaps

• Illiteracy

• Patients with clinically significant Parkinson's Disease

• Patients not expected to be able to complete the 3 month postoperative test

• Sick sinus syndrome without pacemaker

• Hypersensitivity to drug or class

• Current 2nd or 3rd degree AV block

• History of clinically significant bradycardia

• Contraindication to the use of an 2A-agonist

• Presence of a major psychiatric condition such as bipolar disorder, major depression, schizophrenia, or dementia

• ASA physical status IV or V